Trial · NCT07906223
Evolution of Gait Parameters in Toddlers With Unilateral Cerebral Palsy
NCT07906223, Completed, National Clinical Center for Neuropsychomotor Recovery for Children Dr. Nicolae Robanescu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evolution of Gait Parameters in Toddlers With Unilateral Cerebral Palsy. Trials, record NCT07906223. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906223
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evolution of Gait Parameters in Toddlers With Unilateral Cerebral Palsy
- NCT number
- NCT07906223
- Status
- Completed
- Enrollment
- 78 participants, actual
- Lead sponsor
- National Clinical Center for Neuropsychomotor Recovery for Children Dr. Nicolae Robanescu
- Conditions
- Unilateral Cerebral Palsy
- Interventions
- gait analysis
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Three-Dimensional Gait Kinematics From Baseline to Follow-Up within the UCP group | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1. | Changes in continuous kinematic waveforms throughout the gait cycle, expressed as joint angles in degrees, assessed by three-dimensional gait analysis and compared between baseline (T1) and follow-up (T2). The assessed variables include pelvic, hip, knee, and ankle angles in the sagittal plane; pelvic and hip angles in the frontal and transverse planes; and the foot progression angle. Differences between assessments will be evaluated using Statistical Parametric Mapping (SPM) in children with unilateral cerebral palsy (UCP), separately for the affected and non-affected sides. |
| Primary | Changes in Spatiotemporal Gait Parameters From Baseline to Follow-Up within the UCP group | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1 | Changes in spatiotemporal gait parameters assessed by three-dimensional gait analysis and compared between baseline (T1) and follow-up (T2). The assessed parameters include normalized gait velocity, cadence (stride per minute), gait cycle duration (s), the duration of stance, swing, single-support, first and second double-support phases (% of the gait cycle), normalized stride length, normalized step length, step width (m). Changes in these parameters will be evaluated in children with unilateral cerebral palsy (UCP), separately for the affected and non-affected sides. |
| Primary | Change in Gait Profile Score (GPS) From Baseline to Follow-Up within the UCP group | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1 | The Gait Profile Score (GPS) is a composite index derived from three-dimensional gait analysis that quantifies the overall deviation of an individual's lower-limb and pelvic kinematic patterns from the mean kinematic patterns of a typically developing reference population. It is calculated as the root mean square average of the Gait Variable Scores (GVS), which quantify deviations in nine key kinematic variables throughout the gait cycle. The GPS is expressed in degrees (°). Higher GPS values indicate greater deviation from the typically developing reference gait pattern and poorer overall gait kinematic quality, whereas lower values indicate a gait pattern closer to the reference pattern. In this study, GPS values will be compared between baseline (T1) and follow-up (T2) in children with unilateral cerebral palsy (UCP), separately for the affected and non-affected sides. |
| Secondary | Between-Group Differences in Gait Kinematics at Baseline and Follow-Up | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1. | Differences in three-dimensional gait kinematic waveforms between children with unilateral cerebral palsy (UCP) and typically developing (TD) children will be assessed separately at baseline (T1) and follow-up (T2). Kinematic variables include pelvic, hip, knee, and ankle angles in the sagittal plane; pelvic and hip angles in the frontal and transverse planes; and the foot progression angle. Kinematic waveforms will be compared throughout the gait cycle using Statistical Parametric Mapping (SPM). In the UCP group, the affected and non-affected sides will be analysed separately and compared with the representative side obtained by averaging the left and right sides in the TD group. Differences between groups will be evaluated at each assessment time point. |
| Secondary | Between-Group Differences in Spatiotemporal Gait Parameters at Baseline and Follow-Up | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1. | Differences in spatiotemporal gait parameters between children with unilateral cerebral palsy (UCP) and typically developing (TD) children will be assessed separately at baseline (T1) and follow-up (T2) using three-dimensional gait analysis. The assessed parameters include normalized gait velocity, cadence (stride per minute), gait cycle duration (s), the duration of stance, swing, single-support, first and second double-support phases (% of the gait cycle), normalized stride length, normalized step length, step width (m). In the UCP group, the affected and non-affected sides will be analysed separately and compared with the representative side obtained by averaging the left and right sides in the TD group. Between-group differences will be evaluated separately at T1 and T2. |
| Secondary | Between-Group Differences in Gait Profile Score at Baseline and Follow-Up | T1: within the first 6 months after acquisition of independent walking; T2: 12-18 months after T1. | Differences in the Gait Profile Score (GPS) between children with unilateral cerebral palsy (UCP) and typically developing (TD) children will be assessed separately at baseline (T1) and follow-up (T2) using three-dimensional gait analysis. The GPS is a composite measure, expressed in degrees (°), that quantifies the overall deviation of an individual's gait kinematics from a typically developing reference gait pattern. It is derived from the root mean square average of the Gait Variable Scores (GVS), which quantify deviations in nine kinematic variables throughout the gait cycle. Higher GPS values indicate greater kinematic deviation, whereas lower values indicate a gait pattern closer to the reference pattern. In the UCP group, GPS values for the affected and non-affected sides will be analysed separately and compared with the representative side obtained by averaging the left and right sides in the TD group. Between-group differences will be evaluated separately at T1 and T2. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906223
GET https://conductscience.org/api/trials/v1/NCT07906223/registered